Table III.
Subgroup analyses of the association between pre-treatment thrombocytosis and overall survival.
| Variable | Number of studies | HR (95%) | Z | P-value | I2 (%) | P-value |
|---|---|---|---|---|---|---|
| Year of publication | ||||||
| 2000–2014 | 5 | 2.916 (1.534–5.543) | 3.26 | 0.001 | 56.9 | 0.055 |
| 2015–2017 | 5 | 2.296 (1.002–5.262) | 1.96 | 0.049 | 88.7 | <0.001 |
| Region | ||||||
| Asia | 5 | 2.207 (0.772–6.311) | 1.48 | 0.140 | 89.0 | <0.001 |
| Europe | 2 | 2.687 (0.823–8.774) | 1.64 | 0.102 | 66.6 | 0.084 |
| America | 3 | 2.874 (1.388–5.952) | 2.84 | 0.004 | 73.4 | 0.023 |
| Number of cases | ||||||
| <150 | 5 | 2.202 (1.388–3.492) | 3.35 | 0.001 | 26.5 | 0.245 |
| >150 | 5 | 2.779 (1.041–7.420) | 2.04 | 0.041 | 91.2 | <0.001 |
| Type of cancer | ||||||
| USPC | 2 | 2.078 (0.969–4.457) | 1.88 | 0.060 | 2.1 | 0.312 |
| Endometrial cancer | 8 | 2.598 (1.355–4.982) | 2.88 | 0.004 | 86.0 | <0.001 |
| Analysis | ||||||
| Multivariate | 9 | 1.733 (1.430–2.100) | 5.61 | <0.001 | 50.9 | 0.038 |
| Single factor | 4 | 1.886 (1.117–3.186) | 2.37 | 0.018 | 63.8 | 0.040 |
| Platelet count cut-off (×103/mm3) | ||||||
| ≥350 | 1 | 1.367 (0.303–6.171) | 0.41 | 0.684 | – | – |
| >400 | 8 | 2.771 (1.382–5.557) | 2.87 | 0.004 | 85.7 | <0.001 |
| Continuous | 1 | 1.714 (1.055–2.785) | 2.18 | 0.030 | – | – |
Pooled analysis was performed by generic inverse variance. USPC, uterine serous papillary carcinoma; HR, hazard ratio; FIGO, International Federation of Gynecology and Obstetrics.